Supplementary Table S1 Characteristics, treatment details, and number of semen samples and s-inhibin B assessments according to treatment.

/

Surgery

(n=232) /

RT

(n =485) /

Cis850mg

(n =381) /

Cis>850mg

(n =93) /

TOTAL

(n =1191) /

P a

Age, years, median (range)

/ / / / / /
/

At treatment

/

29 (16-58)

/

35 (18-57)

/

29 (15-55)

/

26 (15-58)

/

31 (15-58)

/

<.001

/

At survey

/

41 (24-65)

/

47 (28-65)

/

42 (23-65)

/

36 (25-64)

/

43 (23-65)

/

<.001

Follow-up, years, median (range)

/

12 (5-21)

/

11 (5-21)

/

12 (4-22)

/

10 (5-20)

/

11 (4-22)

/

.001

Histology

/ / / / / /

<.001 b

/

Seminoma

/

8 (3%)

/

483 (99%)

/

75 (20%)

/

12 (13%)

/

579 (49%)

/
/

Nonseminoma

/

224 (97%)

/

2 (1%)

/

306 (80%)

/

81 (87%)

/

613 (51%)

/

Initial RMH-stage c, N (%)

/ / / / / /

<.001 b

/

I

/

226 (97%)

/

462 (95%)

/

131 (34%)

/

11 (12%)

/

830 (70%)

/
/

IM/II

/

6 (3%)

/

23 (5%)

/

180 (47%)

/

27 (29%)

/

237 (20%)

/
/

III

/ / /

18 (5%)

/

9 (10%)

/

27 (2%)

/
/

IV

/ / /

52 (14%)

/

46 (49%)

/

98 (8%)

/

In chemotherapy groups:

/ / / / / /
/

First chemotherapy regimen, N (%)

/ / / / / /
/

CVB

/ / /

146 (38%)

/

12 (13%)

/ /
/

BEP

/ / /

192 (51%)

/

67 (72%)

/ /
/

EP

/ / /

6 (2%)

/

0

/ /
/

CEB

/ / /

19 (5%)

/

1 (1%)

/ /
/

BOP/VIP

/ / /

0

/

12 (13%)

/ /
/

HOP

/ / /

5 (1%)

/

0

/ /
/

Carboplatin, monotherapy

/ / /

8 (2%)

/

0

/ /
/

Other

/ / /

5 (1%)

/

1 (1%)

/ /
/

Administered second line chemotherapy, N (%)

/ / /

31 (8%)

/

46 (50%)

/ /
/

Administered third line chemotherapy, N (%)

/ / /

0

/

10 (11%)

/ /
/

Cisplatin dose, median (range) d

/ / /

740

(185-850)

/

1155

(855-3095)

/ /
/

Carboplatin dose, median (range) d

/ / /

2990

(710-3710)

/

2425

(1590-3600)

/ /
/

Additional treatment, N (%)

/ / / / / /
/

RPLND

/ / /

234 (61%)

/

72 (77%)

/ /
/

RT

/ / /

40 (10%)

/

8 (9%)

/ /

Semen samples delivered, N (%)

/

81 (35%)

/

136 (28%)

/

104 (27%)

/

21 (23%)

/

342 (29%)

/

S-inhibin B available, N (%)

/

122 (53%)

/

213 (44%)

/

81 (21%)

/

25 (27%)

/

441 (37%)

/

Abbreviations: RMS = Royal Marsden Hospital; CVB = cisplatin, vinblastine and bleomycin; BEP = bleomycin, etoposide, cisplatin; EP = etoposide, cisplatin; CEB = carboplatin, etoposide, bleomycin; BOP = bleomycin, vincristine, cisplatin; VIP = etoposide, ifosfamide, cisplatin; HOP = ifosfamide, vincristine, cisplatin

a Kruskal Wallis, exact using Monte Carlo method, except when indicated

b Exact chi square

c According to Peckham et al. 23

d In men where these drugs were administered (carboplatin was administered in 28 cases in the Cis<850 mg group of whom four also received cisplatin-based regimens. Four cases in the Cis>850 mg received carboplatin, all in addition to cisplatin-based regimens)